HURA Company Profile and Key Details

HURA has shown weak momentum, losing -4.82% over the past week and -71.63% over the past quarter, though year-to-date performance is down -10.03%. Short-term trend indicators are mixed aligned (SMA20 60.48%, SMA50 88.99%, SMA200 -23.68%). The stock’s 14-day RSI is 72.4 (overbought), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -63.51% below its high and over 295.12% above its low. Average 10-day trading volume of 182.05 thousand shares is below the 3-month average of 542.55 thousand, indicating normal recent market interest.

TuHURA Biosciences, Inc. generated EPS of -$0.65 over the past year. Five-year average earnings growth is 76.02%. Wall Street analysts project EPS growth of 62.73% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $8.00. The high target offers 453.0% upside. The low target suggests 268.66% downside. The mean target is $8.58. This offers 295.39% upside. TuHURA Biosciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 15, 2026, missed forecasts by 8.33%. The prior quarter beat by 1.35%. Over the last six quarters, Apple has recorded several small beats. These include 9222.22% in February 26, 2025.

The stock is currently mid-range between its 52-week high and low $0.41 and $3.90. With a market capitalization of about $138.19 million, TuHURA Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.04). Key stats such as the average daily volume over the past year has been around 544.19 thousand shares, volume is running light vs its 52-week average. Headquartered in Tampa, FL, TuHURA Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James A. Bianco, the company employs approximately 22 people and listed since February 22, 2013. TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development.

TuHURA Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.06. This means the shares are trading above this model’s fair value.

TuHURA Biosciences, Inc. has 63.68 million shares outstanding. The public float is 39.66 million shares, elevated short interest at 13.50% of float. This equals 6.65 million shares. The short ratio is 9.07 days. Institutional investors hold 22.77% of the float. Insiders own 34.65%.

TuHURA Biosciences, Inc. trades at a P/E ratio of -3.49, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.54 trading at moderately above to book value. The P/FCF stands at -4.98, also below market averages.

Our AI price prediction model suggests that TuHURA Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.99%, with price expected at $2.04 by August 13, 2026, within a range of $1.90 to $2.18 3-Month Outlook: Projected fall of -43.32%, reaching $1.23 by October 28, 2026, with a range of $1.04 to $1.39. 1-Year Outlook: Projected loss of -95.85%, with price at $0.09 by July 30, 2027, within a range of $0.00 to $56.93.

TuHURA Biosciences, Inc. (NASDAQ:HURA) shares are down -10.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows TuHURA Biosciences, Inc. trading at a premium to the broader market with a P/E of -3.49. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $9.27, suggesting 327.19% upside. Our AI forecast model points to short-term weakness (-5.99% over two weeks), a medium-term fall (-43.32% over three months), and a longer-term loss (-95.85% over one year), with expected trading ranges indicating moderate volatility.